CAMP4 Therapeutics Initiates Human Trials for SYNGAP1 Rare Disease Treatment
CAMP4 Therapeutics has received approval from Australia's drug regulator to begin clinical trials for a treatment targeting SYNGAP1-related disorders, a rare genetic condition characterized by epilepsy and neurodevelopmental delays. This trial marks the first human use of the antisense oligonucleotide (ASO) therapy, aiming to assess its safety, efficacy, and dosing. SYNGAP1 mutations are linked to significant intellectual disabilities, and the trial represents a critical step in addressing the unmet medical needs of affected patients. 
